These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 17047047)
21. EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model. Peng W; Huang X; Yang D Int Immunopharmacol; 2014 Aug; 21(2):336-41. PubMed ID: 24861249 [TBL] [Abstract][Full Text] [Related]
22. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650 [TBL] [Abstract][Full Text] [Related]
24. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes. Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222 [TBL] [Abstract][Full Text] [Related]
26. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302 [TBL] [Abstract][Full Text] [Related]
27. The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1. Arvand A; Welford SM; Teitell MA; Denny CT Cancer Res; 2001 Jul; 61(13):5311-7. PubMed ID: 11431376 [TBL] [Abstract][Full Text] [Related]
28. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells. Li X; Tanaka K; Nakatani F; Matsunobu T; Sakimura R; Hanada M; Okada T; Nakamura T; Iwamoto Y Int J Cancer; 2005 Sep; 116(3):385-94. PubMed ID: 15818598 [TBL] [Abstract][Full Text] [Related]
29. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Abaan OD; Levenson A; Khan O; Furth PA; Uren A; Toretsky JA Oncogene; 2005 Apr; 24(16):2715-22. PubMed ID: 15782144 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors. Li Y; Tanaka K; Fan X; Nakatani F; Li X; Nakamura T; Takasaki M; Yamamoto S; Iwamoto Y Cancer Lett; 2010 Aug; 294(1):57-65. PubMed ID: 20153576 [TBL] [Abstract][Full Text] [Related]
31. Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Spahn L; Petermann R; Siligan C; Schmid JA; Aryee DN; Kovar H Cancer Res; 2002 Aug; 62(16):4583-7. PubMed ID: 12183411 [TBL] [Abstract][Full Text] [Related]
32. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Erkizan HV; Uversky VN; Toretsky JA Clin Cancer Res; 2010 Aug; 16(16):4077-83. PubMed ID: 20547696 [TBL] [Abstract][Full Text] [Related]
33. Suppression of the Ewing's sarcoma phenotype by FLI1/ERF repressor hybrids. Athanasiou M; LeGallic L; Watson DK; Blair DG; Mavrothalassitis G Cancer Gene Ther; 2000 Aug; 7(8):1188-95. PubMed ID: 10975680 [TBL] [Abstract][Full Text] [Related]
34. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Aryee DN; Niedan S; Kauer M; Schwentner R; Bennani-Baiti IM; Ban J; Muehlbacher K; Kreppel M; Walker RL; Meltzer P; Poremba C; Kofler R; Kovar H Cancer Res; 2010 May; 70(10):4015-23. PubMed ID: 20442286 [TBL] [Abstract][Full Text] [Related]
35. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119 [TBL] [Abstract][Full Text] [Related]
36. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923 [TBL] [Abstract][Full Text] [Related]
37. The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity. Myatt SS; Burchill SA Oncogene; 2008 Feb; 27(7):985-96. PubMed ID: 17700534 [TBL] [Abstract][Full Text] [Related]
38. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607 [TBL] [Abstract][Full Text] [Related]
39. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Ban J; Bennani-Baiti IM; Kauer M; Schaefer KL; Poremba C; Jug G; Schwentner R; Smrzka O; Muehlbacher K; Aryee DN; Kovar H Cancer Res; 2008 Sep; 68(17):7100-9. PubMed ID: 18757425 [TBL] [Abstract][Full Text] [Related]